Stephens resumed coverage on Ligand Pharma with a new price target
$LGND
Biotechnology: Pharmaceutical Preparations
Health Care
Stephens resumed coverage of Ligand Pharma with a rating of Overweight and set a new price target of $200.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/10/2025 | $143.00 | Buy | Stifel |
| 10/3/2024 | $135.00 | Outperform | Oppenheimer |
| 7/30/2024 | $130.00 | Outperform | RBC Capital Mkts |
| 2/22/2022 | $180.00 → $130.00 | Buy | Benchmark |
| 2/18/2022 | $185.00 → $165.00 | Overweight | Barclays |
| 9/22/2021 | $174.00 → $180.00 | Overweight | Barclays |
| 7/30/2021 | $200.00 → $190.00 | Buy | Roth Capital |